Tat-mediated peptide intervention in analgesia and anesthesia

Feng Tao, Roger A Johns

Research output: Contribution to journalArticle

Abstract

(Table Presented) Membrane-permeable peptide carriers are attractive drug delivery tools. Among such carriers, the protein transduction domain (PTD) of the human immunodeficiency virus-type 1 Tat protein is most frequently used and has been successfully shown to deliver a large variety of cargoes. The Tat PTD can facilitate the uptake of large, biologically active molecules into mammalian cells; recent studies have shown that it can mediate the delivery of different cargoes into tissues throughout a living organism. Given that the Tat PTD-mediated delivery is size-independent, this technology could make previously non-applicable large molecules usable to modulate biological function in vivo and treat human diseases. It is likely that the peptide carrier-mediated intracellular delivery process encompasses multiple mechanisms, but endocytic pathways are the predominant internalization routes. Tat PTD has been successfully used in preclinical models for the study of cancer, ischemia, inflammation, analgesia, and anesthesia. Our recent studies have shown that intraperitoneally injected fusion Tat peptide Tat-PSD-95 PDZ2 can be delivered into the spinal cord to dose-dependently disrupt protein-protein interactions between PSD-95 and NMDA receptors. This peptide significantly inhibits chronic inflammatory pain and reduces the threshold for halothane anesthesia. The ability of the Tat PTD to target any cell is advantageous in some respects. However, the drug delivery system will be more attractive if we can modify the Tat PTD to deliver cargo only into desired organs to avoid possible side effects.

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalDrug Development Research
Volume71
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

tat Gene Products
Anesthesia and Analgesia
Peptides
Drug Carriers
Pain Threshold
Aptitude
Halothane
Drug Delivery Systems
N-Methyl-D-Aspartate Receptors
Chronic Pain
Protein Domains
HIV-1
Spinal Cord
Carrier Proteins
Proteins
Ischemia
Anesthesia
Inflammation
Technology
Membranes

Keywords

  • Minimum alveolar anesthetic concentration
  • Pain modulation
  • Protein transduction domain
  • Protein-protein interaction

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Tat-mediated peptide intervention in analgesia and anesthesia. / Tao, Feng; Johns, Roger A.

In: Drug Development Research, Vol. 71, No. 2, 04.2010, p. 99-105.

Research output: Contribution to journalArticle

@article{44f28161578d43cfb34ef7c3654ab5a2,
title = "Tat-mediated peptide intervention in analgesia and anesthesia",
abstract = "(Table Presented) Membrane-permeable peptide carriers are attractive drug delivery tools. Among such carriers, the protein transduction domain (PTD) of the human immunodeficiency virus-type 1 Tat protein is most frequently used and has been successfully shown to deliver a large variety of cargoes. The Tat PTD can facilitate the uptake of large, biologically active molecules into mammalian cells; recent studies have shown that it can mediate the delivery of different cargoes into tissues throughout a living organism. Given that the Tat PTD-mediated delivery is size-independent, this technology could make previously non-applicable large molecules usable to modulate biological function in vivo and treat human diseases. It is likely that the peptide carrier-mediated intracellular delivery process encompasses multiple mechanisms, but endocytic pathways are the predominant internalization routes. Tat PTD has been successfully used in preclinical models for the study of cancer, ischemia, inflammation, analgesia, and anesthesia. Our recent studies have shown that intraperitoneally injected fusion Tat peptide Tat-PSD-95 PDZ2 can be delivered into the spinal cord to dose-dependently disrupt protein-protein interactions between PSD-95 and NMDA receptors. This peptide significantly inhibits chronic inflammatory pain and reduces the threshold for halothane anesthesia. The ability of the Tat PTD to target any cell is advantageous in some respects. However, the drug delivery system will be more attractive if we can modify the Tat PTD to deliver cargo only into desired organs to avoid possible side effects.",
keywords = "Minimum alveolar anesthetic concentration, Pain modulation, Protein transduction domain, Protein-protein interaction",
author = "Feng Tao and Johns, {Roger A}",
year = "2010",
month = "4",
doi = "10.1002/ddr.20331",
language = "English (US)",
volume = "71",
pages = "99--105",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Tat-mediated peptide intervention in analgesia and anesthesia

AU - Tao, Feng

AU - Johns, Roger A

PY - 2010/4

Y1 - 2010/4

N2 - (Table Presented) Membrane-permeable peptide carriers are attractive drug delivery tools. Among such carriers, the protein transduction domain (PTD) of the human immunodeficiency virus-type 1 Tat protein is most frequently used and has been successfully shown to deliver a large variety of cargoes. The Tat PTD can facilitate the uptake of large, biologically active molecules into mammalian cells; recent studies have shown that it can mediate the delivery of different cargoes into tissues throughout a living organism. Given that the Tat PTD-mediated delivery is size-independent, this technology could make previously non-applicable large molecules usable to modulate biological function in vivo and treat human diseases. It is likely that the peptide carrier-mediated intracellular delivery process encompasses multiple mechanisms, but endocytic pathways are the predominant internalization routes. Tat PTD has been successfully used in preclinical models for the study of cancer, ischemia, inflammation, analgesia, and anesthesia. Our recent studies have shown that intraperitoneally injected fusion Tat peptide Tat-PSD-95 PDZ2 can be delivered into the spinal cord to dose-dependently disrupt protein-protein interactions between PSD-95 and NMDA receptors. This peptide significantly inhibits chronic inflammatory pain and reduces the threshold for halothane anesthesia. The ability of the Tat PTD to target any cell is advantageous in some respects. However, the drug delivery system will be more attractive if we can modify the Tat PTD to deliver cargo only into desired organs to avoid possible side effects.

AB - (Table Presented) Membrane-permeable peptide carriers are attractive drug delivery tools. Among such carriers, the protein transduction domain (PTD) of the human immunodeficiency virus-type 1 Tat protein is most frequently used and has been successfully shown to deliver a large variety of cargoes. The Tat PTD can facilitate the uptake of large, biologically active molecules into mammalian cells; recent studies have shown that it can mediate the delivery of different cargoes into tissues throughout a living organism. Given that the Tat PTD-mediated delivery is size-independent, this technology could make previously non-applicable large molecules usable to modulate biological function in vivo and treat human diseases. It is likely that the peptide carrier-mediated intracellular delivery process encompasses multiple mechanisms, but endocytic pathways are the predominant internalization routes. Tat PTD has been successfully used in preclinical models for the study of cancer, ischemia, inflammation, analgesia, and anesthesia. Our recent studies have shown that intraperitoneally injected fusion Tat peptide Tat-PSD-95 PDZ2 can be delivered into the spinal cord to dose-dependently disrupt protein-protein interactions between PSD-95 and NMDA receptors. This peptide significantly inhibits chronic inflammatory pain and reduces the threshold for halothane anesthesia. The ability of the Tat PTD to target any cell is advantageous in some respects. However, the drug delivery system will be more attractive if we can modify the Tat PTD to deliver cargo only into desired organs to avoid possible side effects.

KW - Minimum alveolar anesthetic concentration

KW - Pain modulation

KW - Protein transduction domain

KW - Protein-protein interaction

UR - http://www.scopus.com/inward/record.url?scp=77951571903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951571903&partnerID=8YFLogxK

U2 - 10.1002/ddr.20331

DO - 10.1002/ddr.20331

M3 - Article

C2 - 20711510

AN - SCOPUS:77951571903

VL - 71

SP - 99

EP - 105

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 2

ER -